CHANGE IN CONTROL SEVERANCE AGREEMENTChange in Control Severance Agreement • January 30th, 2013 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
This Agreement is entered into as of the 30th day of November, 2012 (the “Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (the “Company”), and Charles Q. Morris (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • January 30th, 2013 • Immunogen Inc • Pharmaceutical preparations • Massachusetts
This Employment Agreement (the “Agreement”), dated as of November 26, 2012 (the “Effective Date”), is made by and between ImmunoGen, Inc., a Massachusetts corporation (the “Company”), and Charles Q. Morris (“Executive”). This Agreement is intended to confirm the understanding and set forth the agreement between the Company and Executive with respect to Executive’s employment by the Company. In consideration of the mutual promises and covenants contained in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby mutually acknowledged, the Company and the Executive hereby agree as follows:
THIRD AMENDMENT TO LICENSE AGREEMENT FOR ANTI-HER2 ANTIBODIESLicense Agreement • January 30th, 2013 • Immunogen Inc • Pharmaceutical preparations
This Third Amendment to License Agreement for Anti-HER2 Antibodies (the “3rd Amendment”) is made effective as of the date of the last signature below (the “3rd Amendment Effective Date”) by and between ImmunoGen, Inc., a Massachusetts corporation (“ImmunoGen”), having its principal business office at 830 Winter Street, Waltham, Massachusetts 02451, and Genentech, Inc., a Delaware corporation (“Genentech”), having its principal business office at 1 DNA Way, South San Francisco, California 94080. ImmunoGen and Genentech are herein sometimes referred to as a “Party” and collectively as the “Parties.”
